Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Avalo Therapeutics director Rita Jain received a new stock option grant. On March 31, 2026, she was granted options to acquire 1,339 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The options were granted fully vested and expire on March 31, 2036. Following this grant, she holds 1,339 options directly as reported in this filing.
Avalo Therapeutics director Kevin Robert Lind received a grant of stock options as part of his compensation. On March 31, 2026, he was awarded options to purchase 1,370 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The filing notes these options were granted on March 31, 2026 and are 100% vested, meaning they are fully exercisable immediately. After this grant, Lind holds options covering 1,370 shares, which expire on March 31, 2036 if not exercised.
Avalo Therapeutics reports that Logos Global and affiliated entities hold 1,285,000 shares, representing 5.6% of common stock. The reporting group states the position comprises 285,000 shares of Common Stock and options to acquire 1,000,000 shares, calculated using 22,788,452 shares outstanding as of March 18, 2026. The filing shows shared voting and shared dispositive power for 1,285,000 shares and zero sole voting or dispositive power. The reporting persons say they are filing jointly, disclaim group membership, and identify the Global Fund as holding the shares for investors.
Avalo Therapeutics director Samantha Truex exercised restricted stock units into common shares. On March 28, the vesting and exercise of 3,166 restricted stock units at $0.00 per unit delivered 3,166 shares of common stock, bringing her direct common stock holdings to 6,333 shares.
These units are part of a grant of 9,500 restricted stock units awarded on August 13, 2024, which vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on her continued service.
Avalo Therapeutics director Aaron Kantoff exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a stated price of $0.00 per share.
After the transaction, Kantoff directly held 6,333 shares of common stock. The restricted stock units were part of a 9,500-unit grant awarded on August 13, 2024, scheduled to vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service. No open-market buy or sell was reported in this filing; it reflects a derivative exercise tied to equity compensation.
Avalo Therapeutics director Gilla Kaplan exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a price of $0.00 per share, reflecting a routine compensation-related equity conversion rather than an open-market trade.
Following the transaction, Kaplan directly held 6,333 shares of Avalo Therapeutics common stock and 3,167 restricted stock units. The restricted stock units convert into common stock on a one-for-one basis and were part of a 9,500-unit grant made on August 13, 2024, vesting in three equal annual installments.
Avalo Therapeutics, Inc. Chief Executive Officer Neil Garry Arthur exercised restricted stock units that converted into common stock and had shares withheld for taxes. He exercised 64,866 restricted stock units into 64,866 shares of common stock at a conversion price of $0.00 per share. To satisfy tax obligations, 21,892 shares of common stock were disposed of at $13.89 per share through tax withholding, rather than an open-market sale. Following these transactions, he directly owns 90,114 shares of common stock. The restricted stock units stem from a 194,600-unit grant made on August 13, 2024, vesting in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.
Avalo Therapeutics, Inc. Chief Financial Officer Christopher Ryan Sullivan reported routine equity compensation activity involving restricted stock units (RSUs). On March 28, 2026, 24,200 RSUs converted on a one-for-one basis into 24,200 shares of common stock at a stated price of $0.00 per share.
Of the resulting common shares, 8,241 were disposed of at $13.89 per share to satisfy tax obligations, leaving 33,297 shares of common stock held directly after the transactions. A prior grant of 72,600 RSUs from August 13, 2024 vests in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.
Avalo Therapeutics director Mitchell Chan exercised restricted stock units that vested into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a conversion price of $0.00 per share.
Following the transaction, Chan directly owned 6,333 shares of Avalo Therapeutics common stock. The restricted stock units convert into common stock on a one-for-one basis and are part of a 9,500-unit grant that vests in three equal annual installments starting March 28, 2025.